Growth factor signalling pathways and their inhibitors coordinate the formation of three-dimensional patterns of vertebrates and invertebrates. Temporal and spatial restriction of the response to a few well-de®ned cells is crucial and needs the integration of positive and negative signals. Recently, Spry has been identi®ed as an inhibitor of ®broblast growth factor (FGF) signalling during Drosophila trachea development. Spry has been described as an intracellular protein that can exert its function in a cell autonomous or a paracrine manner. Here we describe the role of SPRY2, a human homologue of Spry, in human FGF2 signalling. We show that in primary human dermal endothelial cells (MVEC) SPRY2 mRNA is transiently upregulated in response to FGF2. Overexpression of SPRY2 in A375 cells leads to the secretion of a soluble factor that inhibits FGF2-but not VEGF-stimulated proliferation of MVEC. Direct administration of recombinant SPRY2 protein has no effect on MVEC proliferation. However, SPRY2 protein binds the intracellular adaptor protein GRB2, indicating an intracellular localization. A SPRY2/GFP fusion protein remains in the cell, further supporting the intracellular localization of SPRY2. So the intracellular protein SPRY2 is involved in the non-cell autonomous inhibitory effect indirectly, via regulating the secretion of an inhibitor of FGF2 signalling in vertebrates, the evidence of which is presented here for the ®rst time. q
Introduction
Pattern formation and organogenesis are important and tightly regulated processes during development of vertebrates and invertebrates. The mechanisms leading to the formation of three-dimensional tubular networks like the insect tracheal system, the mammalian lung epithelium and the vascular system are under extensive investigation. Growth factor signalling pathways and their inhibitors play important roles in the spatial and temporal regulation of pattern formation.
Fibroblast growth factors (FGFs) can stimulate the proliferation and differentiation of many cell types (Saksela et al., 1987; Schweigerer et al., 1987; Yamaguchi and Rossant, 1995) and were discovered to be involved in the formation of all three tubular networks mentioned above (Saksela et al., 1987; Schweigerer et al., 1987; Peters et al., 1994; Sutherland et al., 1996) . Thereby, the restriction of FGF signalling to a few well-de®ned cells is an important aspect of coordinated pattern formation and needs the integration of positive and negative signals (Leevers, 1999) . Recently, Sprouty (Spry) was identi®ed as a novel antagonist of FGF signalling during trachea development in Drosophila (Hacohen et al., 1998; Kramer et al., 1999) . Locally restricted expression of Spry limits FGF induced branching to the tips of growing primary tracheal sprouts (Hacohen et al., 1998) . It has been reported that Spry function is mediated in a paracrine manner as a negative feedback loop upon FGF induction (Hacohen et al., 1998) . Initially Spry was looked upon as an extracellular or secreted protein without clear apprehension whether FGF inhibition is a direct or indirect function of Spry (Hacohen et al., 1998) . Recently, evidence was presented that Spry is localized in the cell, tightly associated with the plasma membrane (Casci et al., 1999) .
For Drosophila Spry at least four murine and three human homologues have been identi®ed so far (Hacohen et al., 1998; deMaximy et al., 1999; Tefft et al., 1999) . Among these SPRY2 shows the strongest sequence conservation to Spry (Hacohen et al., 1998) .
The aim of this work is to contribute to the understanding of FGF-mediated pattern formation in the human system. We focused on the mechanism of SPRY2 action in human cells. In particular, the cellular localization and involvement in a paracrine FGF2 inhibition of SPRY2 was investigated.
Results

SPRY2 is a FGF2-responsive gene
To determine whether SPRY2 mRNA is regulated in www.elsevier.com/locate/modo human cells in response to FGF2, we stimulated primary human dermal endothelial cells (MVEC) with FGF2 for different length of time. As shown in Fig. 1A , SPRY2 mRNA is rapidly upregulated in response to FGF2, reaching maximum expression after approximately 1 h. Then SPRY2 expression declines again. So SPRY2 is directly and transiently upregulated in human endothelial cells in response to FGF2. This corresponds well to in situ hybridization data derived from chicken embryos, where Spry2 expression was highest 1 h after implantation of FGF4-beads (Minowada et al., 1999) .
Structure of SPRY2 protein
The SPRY2 mRNA encodes a 315-amino-acid (aa) polypeptide with a predicted molecular mass of 35 kDa. Human SPRY2 and Drosophila Spry share three stretches of homology, two short domains near the N-terminus and one 124aa-long cysteine-rich domain at the C-terminus (Hacohen et al., 1998) , shown as grey and dark-grey boxes in Fig. 1B . This cysteine-rich region is most conserved between Spry and SPRY2 (51% identity, with 21 cysteines being conserved). In contrast to Spry, SPRY2 seems to have no predictable signal peptide (Hacohen et al., 1998; Fig. 1B) and shows only one potential glycosylation site at N 9 compared with eight potential sites in Spry. Within the cysteine-rich region of SPRY2 there is a clearly predictable transmembrane domain (predicted by TMpred), shown in Fig. 1B as a black box. Based on these ®ndings it is unlikely that SPRY2 represents a secreted protein.
SPRY2 is located in the cell
To investigate whether SPRY2 gets secreted by human cells, we prepared two eukaryotic expression constructs as C-terminal GFP fusion proteins. The ®rst comprised the full-length open reading frame from M 1 to T 315 and was called SPRY2/GFP. The second construct SPRY2DC/GFP was truncated at the C-terminus, directly upstream of the predicted transmembrane domain and extended from M 1 to T 251 , as shown in Fig. 1B . These constructs were transfected transiently in A375 cells. After 2 days the cells were analyzed by¯uorescence microscopy. As expected, the positive control expressing GFP alone showed an even distribution of GFP over the complete cell, leaving only the nucleoli unstained ( Fig. 2A) . The SPRY2DC/GFP fusion protein was distributed diffusely in the cytoplasm, but did not enter the nucleus ( Fig. 2A) , whereas SPRY2/GFP was bound to membranous structures in the cell ( Fig. 2A) . To prove the localization of the GFP fusion proteins, the transiently transfected cells were disrupted and separated into the cytosolic and membrane fraction. Conditioned media of the transient transfections, the cytosolic and membrane fractions were analyzed in a Western blot experiment using anti- Fig. 1 . FGF2 regulation and domain structure of SPRY2. (A) MVEC were stimulated with FGF2 for different time intervals and SPRY2 mRNA expression was determined by Northern blot. SPRY2 is transiently upregulated in response to FGF2 with highest expression after 1 h of induction. b -Actin was used as control for equal loading. (B) The transmembrane prediction plot was generated using TMpred. In the domain structure panel, regions of homology to Drosophila Spry are shown in grey and dark-grey boxes, and the TM domain within the cysteine-rich region is represented as black box. SPRY2 represents the full-length SPRY2 protein, SPRY2DC represents a C-terminally truncated version, lacking the potential transmembrane domain.
GFP antibodies for detection. While the C-terminally truncated SPRY2DC/GFP fusion protein was detectable in the cytosolic and membrane fraction, the full-length SPRY2/ GFP appeared only in the membrane fraction (Fig. 2C) . Furthermore, we could not detect any fusion protein in the conditioned media of SPRY2-transfected cells (Fig. 2B ). So SPRY2 is not secreted, but located intracellularly in association with the cell membrane. This is in agreement with the recent ®nding that Drosophila Spry is located in the cell, tightly associated with the inner surface of the plasma membrane (Casci et al., 1999) .
SPRY2 binds to GRB2
To further support the intracellular localization of SPRY2, we tried to identify binding partners using recombinant SPRY2 protein in a His-tag`pull down' experiment. Full-length 6xHis-tagged SPRY2 was insoluble, but 6xHis-tagged SPRY2DC lacking the hydrophobic region near the C-terminus was soluble under native conditions. Puri®ed recombinant 6xHis-tagged SPRY2DC was prebound to a Ni-NTA column. A375 cells were lysed and loaded on the column. The column was washed very stringently, bound proteins were eluted and analyzed by Western blotting. As shown in Fig. 3A , we were able to detect GRB2 in the SPRY2DC lane, but not in the negative control. There were no detectable amounts of Ras-Gap1 (Fig. 3A) , SOS1 or PI3K in the fraction of bound proteins (data not shown). To further con®rm the SPRY2±GRB2 interaction, we transiently transfected A375 cells with either full-length SPRY2/GFP or the C-terminally truncated SPRY2DC/ GFP expression constructs. The fusion proteins were immunoprecipitated using an anti-GFP antibody and analyzed on a Western blot using an anti-GRB2 antibody for detection. As shown in Fig. 3B , coprecipitating GRB2 protein was detected in the precipitate of SPRY2/GFP and SPRY2DC/ GFP-transfected cells but not in the untransfected or GFPtransfected controls. These ®ndings corroborate data from Drosophila, where Spry is shown to bind to Drk, the Drosophila homologue of GRB2 (Casci et al., 1999) .
Stable transfection of SPRY2 and SPRY2D C in A375 cells
To test whether SPRY2 acts in a cell-autonomous or a paracrine manner, we separated the process in two parts, a signal emitter and a responder cell. As signal emitter we prepared stably transfected A375 cell lines. Two constructs, one comprising full-length SPRY2 and one expressing the C-terminally truncated SPRY2DC (Fig. 1B) were transfected into A375 cells. While we had no problems getting stable SPRY2DC clones under the conditions used, we were The cellular localization of SPRY2 was determined using GFP fusion proteins. A375 cells were transfected with full-length SPRY2/GFP, a C-terminally truncated version SPRY2DC/GFP or GFP alone. The transfection was performed for 6 h using LipofectAMINE. (A) The transiently transfected cells were incubated for 40 h and then analyzed by¯uorescence microscopy. The expression of GFP and GFP fusion proteins is shown with GFP control on the left, SPRY2DC/GFP on the right and SPRY2/GFP in the middle. (B) Conditioned media of these transfected cells were analyzed by Western blot experiments using anti-GFP antibodies to check for fusion proteins. Neither SPRY2/GFP (,60 kDa) nor SPRY2DC/GFP (,52 kDa) were detectable in the supernatants. (C) Subcellular fractions of two independently transfected cell populations (A,B) were analyzed by Western blot experiments using anti-GFP antibodies to localize fusion proteins. SPRY2/GFP (,60 kDa) was found exclusively in the membrane fraction, whereas SPRY2DC/GFP (,52 kDa) was detectable also in the cytosolic fraction. not able to establish stably transfected A375 cells expressing full-length SRPY2. Transfection with SPRY2DC led to several clones expressing SPRY2DC mRNA at different levels as measured by reverse transcriptase±polymerase chain reaction (data not shown). Morphologically we could not see a difference between wild-type and SPRY2DC-transfected A375 cells. To check whether SPRY2DC overexpression had an effect on cell proliferation or renders the cells sensitive for FGF2 stimulation, we performed proliferation assays with two A375 clones expressing different levels of SPRY2DC. A375 cells expressing SPRY2DC did not show an altered proliferation rate compared with wild-type or mock-transfected A375 cells and were not rendered FGF2-dependent (data not shown). To check whether SPRY2DC overexpression had an effect on the secretion of FGF2, VEGF or the known inhibitor of endothelial cell proliferation, TGF-b 1, we measured the amount of these growth factors in the conditioned media. As shown in Table 1 , SPRY2DC overexpression had no effect on the secretion of these growth factors by A375 cells.
SPRY2D C induces the secretion of an antiproliferative factor in A375 cells
As signal responder cell we selected MVEC, because MVEC growth and survival can be stimulated by VEGF and FGF2 in a concentration dependent manner (Saksela et al., 1987; Schweigerer et al., 1987; Piossek et al., 1999) . In order to determine whether SPRY2DC-transfected A375 clones might exert an inhibitory effect on FGF2-responsive cells, we added the conditioned supernatants of the transfected A375 clones to FGF2-or VEGF-stimulated MVEC and measured their proliferation. As shown in Fig.  4A , conditioned media from two clones expressing SPRY2DC at different levels inhibited FGF2-stimulated proliferation of MVEC to ,30% of control or to baseline levels, respectively. This effect was dose-dependent, since the clone SPRY2DCa expressing less SPRY2DC showed also less inhibition. The same supernatants had no effect on VEGF-stimulated proliferation (Fig. 4A) . Supernatants of wild-type or mock-transfected A375 did not inhibit growth factor-stimulated proliferation of MVEC. A375 cell-conditioned media had some additional stimulatory effect on growth factor induced proliferation as compared with controls, what might be due to latent VEGF secretion by A375 cells (Table 1; Siemeister et al., 1999) .
Full-length SPRY2 shows the same effect
To test whether full-length SPRY2 has the same effect as SPRY2DC, we transiently transfected A375 cells either with the full-length SPRY2 or with the SPRY2DC expression construct. Conditioned media were collected as before and subjected to MVEC proliferation tests induced either by FGF2 or VEGF. As shown in Fig. 4B , supernatants of SPRY2 and SPRY2DC-transfected cells moderately but signi®cantly (P , 0:05) inhibited FGF2-stimulated growth of MVEC. The same supernatants had no effect on VEGFstimulated MVEC proliferation.
To ®nd out whether SPRY2 itself has an effect on MVEC proliferation recombinant 6xHis-SPRY2DC, which was Western analysis of 6xHis-tagged SPRY2DC`pull down'. 6xHis-tagged SPRY2DC protein was prebound to a Ni-NTA column and A375 lysate was loaded onto the column. The column was washed stringently and bound proteins were eluted. A Western blot analysis using GRB2-and Ras-GAP1-speci®c antibodies was performed. Positive control, PC-12 cell lysate; negative control, eluate of A375 lysate run over untreated Ni-NTA column; rSPRY2DC bound, eluate of A375 lysate run over 6xHis-tagged SPRY2DC prebound Ni-NTA column. (B) Western analysis of SPRY2/GFP immunoprecipitation. A375 cells were transfected with truncated SPRY2DC/GFP or full-length SPRY2/GFP expression constructs, fusion proteins were immunoprecipitated as described and analyzed using an anti-GRB2 antibody for detection. Positive control, PC-12 cell lysate; wt, precipitate of untransfected cells; GFP, precipitate of GFP-transfected cells; SPRY2DC/GFP, precipitate of cells transfected with SPRY2DC/GFP construct; SPRY2/GFP, precipitate of cells transfected with SPRY2/GFP construct. shown to bind to GRB2, was added in increasing amounts to FGF2-or VEGF-stimulated MVEC. We detected no effect on MVEC growth stimulation by either factor, even at very high concentrations of recombinant SPRY2DC protein (data not shown).
Discussion
During development the formation of three-dimensional networks like the insect tracheal system, the mammalian lung epithelium and the vascular system is a tightly regulated process. One important aspect of these sprouting processes is the restriction of an inducing signal to a few well-de®ned cells in order to form a coordinated pattern. The limitation in response of otherwise equal cells can be achieved by temporally and spatially differential concentrations of the inducing factor and by a downregulation of neighbouring cells. Spry has been described as an inhibitor of FGF signalling in Drosophila tracheal sprouting with such a non-cell-autonomous function (Hacohen et al., 1998) .
In this study we asked whether human SPRY2 is regulated in response to FGF2 and may exert a paracrine negative feedback on the human FGF2 signalling pathway comparable to that in Drosophila.
We showed that SPRY2 is transiently upregulated in response to FGF2. These ®ndings are in agreement with recent reports demonstrating the upregulation of several Spry homologues in mouse and chicken embryos near FGF signalling centres or directly in response to an FGF4-bead (Minowada et al., 1999; Tefft et al., 1999; Chambers and Mason, 2000) . So SPRY2 may play an important role in the regulation of the human FGF2 signalling pathway.
To ®nd out whether SPRY2 acts as a secreted factor, we investigated its cellular localization. We performed expression studies using GFP fusion proteins and Western blot analysis to demonstrate that SPRY2 is not secreted but remains in the cell associated with the cellular membrane After 3 days in culture, cell mass was determined using alamarBlue test (n 4; mean^SD; *P , 0:05, **P , 0:01 with respect to mock control). Panels given represent one out of three independent experiments. (A) Conditioned media of two A375 clones (SPRY2DCa, SPRY2DCb) stably transfected with SPRY2DC signi®cantly inhibit FGF2-induced proliferation compared with wild-type and mock controls, but have no effect on VEGF-induced MVEC proliferation. (B) Conditioned media of A375 cells transiently transfected with full-length SPRY2 or SPRY2DC signi®cantly inhibit FGF2 driven proliferation of MVEC compared with mock control, but have no effect on VEGF-induced growth. wt, untransfected A375; mock, vector-transfected A375; SPRY2DCa, A375 clone SPRY2DCa; SPRY2DCb, A375 clone SPRY2DCb.
fraction. Further, we showed that the C-terminus of SPRY2 containing the potential transmembrane domain is crucial for membrane localization. In Drosophila the cellular localization of Spry is still under discussion. Originally Spry was described as an extracellular secreted protein (Hacohen et al., 1998) . Recently Casci et al. (1999) showed that Spry is located intracellularly, tightly associated with the inner surface of the plasma membrane, with neither the N-terminus nor the C-terminus facing the extracellular side. Further, they demonstrated that the C-terminal cysteine-rich domain, the region most conserved between Spry and SPRY2, is also crucial for Drosophila Spry protein to associate with the plasma membrane. In addition, Casci et al. (1999) showed that Spry binds Drk and Gap1, two intracellular components of the Ras pathway, further supporting the intracellular localization of Spry. By`pull down' and coimmunoprecipitation experiments we showed that SPRY2 binds GRB2, the human homologue of Drk, in human cells. These ®ndings support the intracellular localization of SPRY2 in human cells and present evidence for a comparable mode of action for Spry in Drosophila and SPRY2 in the human system.
In Drosophila Spry has been reported to act non-cellautonomously in inhibiting the FGF signalling pathway (Hacohen et al., 1998) . To test whether this holds true for the human FGF2 signalling pathway, we separated the process into two parts, a signal emitter and a responder cell. As signal emitter we used two A375 cell lines stably transfected with SPRY2DC. Conditioned media of these cells were used in proliferation tests using MVEC as responder cells. We clearly showed that supernatants of SPRY2DC-transfected cells speci®cally inhibit FGF2-dependent growth of MVEC, whereas VEGF-induced growth was unaffected. In a second experiment we demonstrated that this paracrine FGF2-speci®c inhibition is also detectable with supernatants of A375 cells transiently transfected with the full-length SPRY2.
Direct administration of recombinant SPRY2DC protein had no effect; further, we found no changes in FGF2, VEGF or TGF-b1 secretion of transfected A375 cells. This indicates that the FGF2 inhibitory effect is not mediated directly by SPRY2 or elevated secretion of TGF-b1. Based on our experiments we present a model for SPRY2-mediated pattern formation. Cells ®rst in contact with a threshold amount of FGF2 respond to the signal and thereby express elevated levels of SPRY2. The intracellular SPRY2 protein binds GRB2 and leads to the secretion of an inhibitor of FGF2 signalling, the nature of which remains to be unravelled. This secreted inhibitor blocks the FGF2 mediated induction of surrounding cells and thereby limits the range of FGF2 signalling to a few wellde®ned cells. This type of patterning mechanism with a negative paracrine feedback loop is comparable to that mediated by Argos in Drosophila, which is an EGF-induced secreted inhibitor of EGF signalling (Freeman et al., 1992; Schweitzer et al., 1995; Leevers, 1999) .
In Drosophila Spry is not speci®c for FGF signalling but plays a role in many receptor tyrosine kinase signalling pathways, such as EGF receptor, Torso and Sevenless (Casci et al., 1999; Kramer et al., 1999; Peri et al., 1999; Reich et al., 1999) . Only in the case of FGF signalling has Spry been shown to mediate a paracrine function (Hacohen et al., 1998) ; in the case of EGF signalling only a cellautonomous function has been demonstrated, probably by inhibiting the Ras/MAPK pathway (Casci et al., 1999; Kramer et al., 1999; Peri et al., 1999; Reich et al., 1999) . Based on our results, we cannot exclude an additional cellautonomous function of SPRY2 in the human system, especially since we found SPRY2 binding to GRB2, a member of the Ras/MAPK pathway. Furthermore, the problems we encountered in establishing an A375 cell line stably overexpressing full-length SPRY2 point to a cell-autonomous function of SPRY2 in addition to the secretion of a paracrine inhibitor of FGF2 signalling.
Interestingly, the overexpression of SPRY2DC or fulllength SPRY2 in A375 cells both lead to the secretion of a soluble inhibitor of FGF2 signalling although their cellular localization is different. In Drosophila a mutation that results in a lack of the cysteine-rich domain responsible for membrane association of Spry behaves like complete Spry 2/2¯i es. So the localization of Spry protein is probably important for its function under naturally occurring expression levels (Hacohen et al., 1998) . In our experiments the SPRY2 constructs were constitutively overexpressed and strong unregulated overexpression of full-length SPRY2 seems to be toxic to the A375 cells. One might speculate whether the SPRY2DC protein under these conditions does not reach a toxic concentration level at the proper site of SPRY2 action, but is suf®ciently present to trigger the secretion of the FGF2 inhibitor. This speculation is supported by the dose-dependent secretion of the inhibitor by the clones expressing different levels of the truncated SPRY2 version, SPRY2DCa and SPRY2DCb.
In summary, we have shown that SPRY2 is transiently upregulated in human endothelial cells in response to FGF2 and that SPRY2 inhibits FGF2 signalling by a secreted factor. We demonstrated that SPRY2 protein itself cannot inhibit FGF2 signalling in a paracrine manner but is located intracellularly and binds GRB2. This report presents for the ®rst time evidence for the existence of a paracrine negative feedback loop in the regulation of the FGF2 signalling pathway in vertebrates. SPRY2 may play an important role in regulating FGF2-driven angiogenesis, since endothelial cells regulate SPRY2 expression in response to FGF2 and are sensitive for the secreted inhibitor of FGF2 signalling.
Experimental procedures
Cell culture
Human microvascular endothelial cells (MVEC) were prepared from human foreskin as described previously (Piossek et al., 1999) . MVEC were cultured in¯asks coated with 10 mg/ml Collagen and in M199 medium containing 10% foetal calf serum, 10% human serum, 2 mM glutamax, penicillin (100 units/ml), streptomycin (100 mg/ml), ascorbic acid (1.27 mM), pyruvic acid (1 mM), 1% non-essential amino acids (Biochrom), 6 mg/ml endothelial growth factor from bovine brain (Sigma) and 7.5 mg/ml heparin (Sigma).
Cell line A375 (American Type Culture Collection CRL 1619) is derived from a human malignant melanoma; the subtype used here shows up-regulated VEGF expression (Siemeister et al., 1999) . A375 cells were cultured in DMEM/Ham's F-12 medium containing 10% foetal calf serum, 2 mM glutamine, penicillin (100 units/ml) and streptomycin (100 mg/ml).
A375 cells and MVEC were passaged by trypsin digestion (0.02% trypsin, 0.01% EDTA in PBS without bivalent ions).
Construction of expression vectors
Full-length SPRY2 and truncated SPRY2DC were ampli®ed by the polymerase chain reaction (PCR) using ®rst-strand cDNA derived from human microvascular endothelial cells (MVEC). Full-length SPRY2 extending from M 1 to T 315 was generated using the primers SPRY2fBam, SPRY2rKpn for the prokaryotic expression vector pQE-30 (Qiagen); SPRY2fKpn, SPRY2rBam for the eukaryotic expression vector pEGFP-N3 (Clontech) and SPRY2Bam, SPRY2rNot for the eukaryotic expression vector pIRES/ Hyg (Clontech). Truncated SPRY2DC extending from M 1 to T 251 was generated using the primers SPRY2fBam, SPRY2DrKpn for pQE-30; SPRY2fKpn, SPRY2DrBam for pEGFP-N3 and SPRY2fBam, SPRY2DrNot for pIRES/Hyg. The PCR products SPRY2 and SPRY2DC were cloned into pQE-30 using restriction sites BamHI and KpnI, pEGFP-N3 using KpnI and BamHI, pIRES/Hyg using BamHI and NotI.
All primer sequences are given in Table 2 . All expression constructs were sequenced (Agowa GmbH) to check for correct inserts.
Expression of recombinant 6xHis-tagged SPRY2 and SPRY2D C in XL-2 blue
A single colony was inoculated in 20 ml LB containing 100 mg/ml ampicillin and 25 mg/ml kanamycin and grown overnight. A 600-ml LB culture was inoculated 1:50 with overnight culture and grown at 378C until the OD 600 reached 0.6. The culture was induced by adding IPTG to a ®nal concentration of 1 mM and grown for additional 5 h. Cells were pelleted at 4000 £ g and frozen overnight at 2808C. The pellet was resuspended in 20 ml native Lysis buffer (50 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl) containing 10 mM imidazole, 1 mg/ml lysozyme. The lysate was soni®ed ten times (10 s, 150 W) and centrifuged for 30 min (48C, 10 000 £ g). The supernatant was loaded on a 4-ml Ni-NTA column. The column was washed with 6 £ 10 ml Lysis buffer raising the imidazole concentration slowly from 10 to 40 mM. The 6xHis-tagged protein was eluted in 10 ml Lysis buffer containing 250 mM imidazole. Purity of the protein was checked by a 12% SDS±PAGE and Coomassie staining. Imidazole was removed by dialysis.
6xHis-tagged SPRY2DC`pull down'
Four milligrams of recombinant 6xHis-tagged SPRY2DC protein was bound to a 1-ml Ni-NTA column. A375 cells, 2 £ 10 8 , were washed two times with PBS and lysed in 20 ml 1£ DUSCHEL buffer (50 mM HEPES, 150 mM NaCl, 1 mM MgCl 2 , 10 mM Ma 2 PO 4 , 100 mM NaF, 1 mM VO 3 , 10% glycerine, 1.2% Triton, 1 protease inhibitor tablet (Boehringer Mannheim) per 50 ml) containing 10 mM imidazole. Cell lysate was homogenized by pulling up and down through a syringe and a 14-gauge needle. Homogenized lysate was centrifuged in a Sorvall SS-34 at 18 000 rev./min and 48C, for 30 min to pellet cellular fragments. Half of the supernatant was loaded at 48C on a 1-ml Ni-NTA column with prebound 6xHis-tagged SPRY2DC. As a negative control the other half of A375 lysate was loaded at 48C on a 1-ml Ni-NTA column without prebound protein. Both columns were washed with 200 ml native Lysis buffer (50 Table 2 Nucleotide sequence of PCR primers Primer Sequence
SPRY2f 5 H -ATGGAGGCCAGAGCTCAGA-3 mM NaH 2 PO 4 (pH 8.0), 300 mM NaCl) slowly raising the imidazole concentration from 10 to 40 mM. Bound proteins were eluted in 2 ml Lysis buffer containing 250 mM imidazole. Aliquots of each column were concentrated 1:10 by lyophilization and 50 ml were run on a 12% SDS±PAGE. Proteins were transferred for 1.5 h at 1 mA/cm 2 onto a PVDF membrane using a semi-dry system. The membrane was blocked for 1 h at room temperature in PBS 1 1% BSA and then incubated for 1 h at room temperature with either an anti-GRB2 mouse-monoclonal antibody or anti RasGap1 mouse-monoclonal antibody (Dianova) 1:5000 in PBS 1 1% BSA. The membrane was washed three times for 15 min with PBS 1 0:1% Tween-20 and incubated for 1 h at room temperature with the second antibody, a 1:50 000 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG polyclonal antibody (Dianova). After washing the membrane for several times with PBS 1 0:1% Tween-20, bound horseradish peroxidase-conjugated antibodies were detected by chemiluminescence using ECL 1 (Amersham Pharmacia Biotech) and exposed to Hyper®lm ECL (Amersham Pharmacia Biotech).
Transient transfection of A375 with pEGFP constructs
A375 cells were seeded in a density of 5 £ 10 5 cells per 10-cm dish and cultured for 2 days before transfection with 3 mg of the expression vector in LipofectAMINE (Gibco BRL). The liposome±DNA complex was spread on the cells and incubated for 6 h. Thereafter the transfection medium was replaced by full cell culture medium.
The transiently transfected cells were incubated for 40 h and then analyzed by¯uorescence microscopy (Zeiss) using a ®lter set suitable for GFP detection.
Stable transfection of A375 with pIRES/Hyg constructs
A375 cells were transfected with pIRES/Hyg as above. Thereafter the transfection medium was replaced by full cell culture medium containing 800 mg/ml Hygromycin B (Calbiochem). After 1 week of culture cells were cloned and individual clones were further characterized.
Preparation of conditioned media from A375
A375 cells (1 £ 10 7 ) were plated into a 225-cm 2¯a sk with the appropriate medium and grown for 24 h. The next day the medium was changed to M199 medium with 2 mM glutamax, penicillin (100 units/ml), streptomycin (100 mg/ml) and 2% human serum. Cells were incubated overnight, medium was removed and centrifuged to pellet the remaining cells. This conditioned medium was mixed 3:2 with fresh M199 medium with 2 mM glutamax, penicillin (100 units/ml), streptomycin (100 mg/ml) and 2% human serum.
Proliferation of A375 cells and MVEC
Thirty thousand cells were plated into a 24-well plate in the appropriate full medium. After 2 h for MVEC and 6 h for A375 cells, the medium was serum-reduced to 2% human serum and cells were grown overnight. Next morning the medium was changed to fresh medium containing 2% human serum or conditioned medium. Various amounts of growth factors or 6xHis-tagged SPRY2DC were added. After 3 days in culture, 1:100 (v/v) alamarBlue (Biosource Int.) was added to the cells. The cells were incubated for 2 h and then the¯uorimetric changes were measured using a Cyto¯uor 2350 reader (Millipore). In earlier experiments quanti®cation was performed with Bengal Rose as described elsewhere (Piossek et al., 1999) . All proliferation assays were performed at least twice in separate experiments.
Northern blot
Total RNA was prepared using RNeasy Mini kit (Qiagen). Twenty micrograms of each total RNA were electrophoresed on a 1% agarose/formaldehyde gel, capillary blotted onto nylon membranes and UV-crosslinked. A SPRY2-speci®c PCR probe was labelled with a random primer labelling kit (Stratagene) using [ 32 P]dCTP. Filter was hybridized in ExpressHyb (Clontech) for 18 h at 688C and washed extensively at high stringency. Filter was exposed to X-ray ®lm (Kodak).
Subcellular fractionation
Transiently transfected A375 cells were washed twice with cold PBS. Cells were scraped in lysis buffer (PBS, 3 M KCl, protease inhibitors) and homogenized by three 3-s bursts using a soni®er (Branson, . The nuclei were removed by centrifuging at 1000 £ g for 20 min at 48C. The membrane fraction was collected by centrifuging at 100 000 £ g for 1 h at 48C and resuspended in an equal amount of lysis buffer. The supernatant represents the cytosolic fraction. Equal amounts of each fraction were loaded on a 10% SDS±PAGE, blotted onto PVDF membrane and analyzed using anti-GFP antibodies (Boehringer Mannheim).
ELISA for VEGF, FGF2 and TGF-b 1
For each transfected A375 clone 1 £ 10 7 cells were plated on a 225-cm 2¯a sk in 50 ml of the appropriate serumreduced medium and grown for three days. The conditioned medium was removed and centrifuged to pellet remaining cells. ELISA for VEGF, FGF2 and TGF-b 1 were performed as suggested by the manufacturer (R&D Systems).
Immunoprecipitation of GFP fusion proteins
A375 cells were transiently transfected with pEGFP, SPRY2/GFP or SPRY2DC/GFP as described. After 2 days the cells were washed two times in PBS and lysed in 1 ml lysis buffer (50 mM Tris±HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, protease inhibitors). After homogenization the lysates were centrifuged at 12 000 £ g for 10 min at 48C, 50 ml of protein G-agarose (Boehringer Mannheim) was added and the lysates were incubated for 5 h at 48C. The agarose was pelleted by centrifugation at 12 000 £ g for 20 s at 48C and 2 mg of anti-GFP antibody (Boehringer Mannheim) was added. After 2 h of incubation at 48C 50 ml protein G-agarose was added and the samples incubated overnight at 48C. The samples were washed twice in lysis buffer, twice in wash buffer 2 (50 mM Tris±HCl (pH 7.5), 500 mM NaCl, 0.1% Nonidet P40, 0.05% sodium deoxycholate) and once in wash buffer 3 (50 mM Tris±HCl (pH 7.5), 0.1% Nonidet P40, 0.05% sodium deoxycholate). The pellets were resuspended in 50 ml gel-loading buffer, subjected to SDS±PAGE and analyzed in a Western blot experiment as described.
